Therapeutic, Humanized Monoclonal Antibody Exhibits Broad Binding and Protective Efficacy against Acinetobacter baumannii.
Acinetobacter baumannii
K antigen
O antigen
antibiotic resistance
carbohydrates
monoclonal antibody
therapeutic
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
16 03 2023
16 03 2023
Historique:
pubmed:
1
3
2023
medline:
21
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
Acinetobacter baumannii is an extremely drug-resistant pathogen necessitating the development of new therapies. We seek to generate a cocktail of monoclonal antibodies (MAbs) that can target the full diversity of A. baumannii isolates. We have newly identified the antibody MAb5. Here, we demonstrate that MAb5 has broad binding against U.S. (
Identifiants
pubmed: 36853012
doi: 10.1128/aac.00086-23
pmc: PMC10019318
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antibodies, Monoclonal
0
O Antigens
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008623Subventions
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 2R01AI130060
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R01AI139052
Références
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32718956
J Infect Dis. 2021 Dec 15;224(12):2133-2147
pubmed: 34036366
Microb Genom. 2022 Oct;8(10):
pubmed: 36214673
Infect Immun. 2021 Sep 16;89(10):e0016221
pubmed: 34310884
Microb Genom. 2020 Mar;6(3):
pubmed: 32118530
Expert Opin Pharmacother. 2010 Apr;11(5):779-88
pubmed: 20210684
J Infect Dis. 2023 Jan 06;:
pubmed: 36617220
J Infect Dis. 2015 Apr 15;211(8):1296-305
pubmed: 25378635
J Infect Dis. 2017 Aug 15;216(4):489-501
pubmed: 28931235